Patent intelligence · US
US 9636334
Combination of lenalidomide and polypeptide construct, and uses thereof
Combination of lenalidomide and polypeptide construct, and uses thereof
Patent details — US 9636334
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 2, 2017
- Expiration
- Apr 27, 2037
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K31/454, A61K38/212
Quick answer
US 9636334 (Combination of lenalidomide and polypeptide construct, and uses thereof) is held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K31/454, A61K38/212, A61K39/39558, A61K45/06
More from TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 9636334?
US 9636334 (Combination of lenalidomide and polypeptide construct, and uses thereof) is held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9636334?
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 9636334 expire?
Our index shows an expiration date of Apr 27, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.